Latest News About Charm

Here are the latest publicly available updates on CHARM Therapeutics:

• CHARM Therapeutics announced a Series B financing of $80 million, led by NEA and SR One, to advance its AI-designed menin inhibitor program for AML, with clinical development expected to start in Q1 2026. This press release was circulated in September 2025, marking a significant milestone for the company.[1]
• In the same period, CHARM shared progress on CHM-029, a next-generation menin inhibitor, highlighted as advancing in preclinical stages and designed to overcome resistance mutations; accompanying materials indicated plans for first-in-human studies, with formal announcements around late 2025 to 2026 window.[2]
• The company has maintained a public-facing news page detailing leadership appointments and strategic milestones, including prior C-suite hires and advisory board developments, with updated items appearing through 2025.[8]

If you’d like, I can summarize the most relevant points for a quick briefing or pull out key timelines and investor names for your records.

Would you like a concise timeline or a one-page briefing with risk and milestone highlights? I can also look for more recent press releases if needed.[1][2][8]